查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1799158

癌症治療新型藥物傳輸系統的全球市場

Novel Drug Delivery Systems in Cancer Therapy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，美國癌症治療新型藥物傳輸系統的全球市場規模將達到 645 億美元

2024年，全球癌症治療新型藥物輸送系統市場規模估計為213億美元，預計到2030年將達到645億美元，在分析期內（2024-2030年）的複合年成長率為20.3%。奈米顆粒是本報告分析的細分市場之一，預計其複合年成長率為18.0%，到分析期結束時市場規模將達到358億美元。栓塞顆粒細分市場在分析期間內的複合年成長率估計為23.6%。

美國市場規模估計為 58 億美元，中國市場預期複合年成長率為 26.9%

預計到2024年，美國癌症治療新型藥物傳輸系統市場規模將達58億美元。作為世界第二大經濟體的中國，預計2030年市場規模將達到150億美元，在2024-2030年的分析期間內，複合年成長率將達到26.9%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為16.4%和18.0%。在歐洲，預計德國市場的複合年成長率約為16.9%。

全球癌症治療中的新型藥物傳輸系統—主要趨勢和促進因素總結

為什麼新的藥物輸送系統可能會顛覆傳統的癌症治療

傳統化療長期以來一直受到全身毒性、生物利用度低和缺乏腫瘤特異性等問題的困擾，這些問題影響了療效和患者的生活品質。新型藥物遞送系統 (NDDS) 能夠將抗癌藥物標靶遞送至腫瘤部位，同時最大限度地減少對健康組織的損害，並迅速成為腫瘤學領域的一項變革性技術。透過改善藥物動力學和克服抗藥性機制，NDDS 正在重新定義臨床醫生治療複雜且異質性癌症類型的方法。

最重要的技術創新是奈米載體，例如脂質體、樹狀聚合物、膠束和聚合物奈米顆粒，它們可以包覆細胞毒性藥物，並使其在腫瘤微環境中實現控釋。這些系統利用在固態腫瘤中觀察到的滲透性和滯留性 (EPR) 效應來實現位點特異性遞送，從而增強治療效果並降低脫靶毒性。此外，已開發出使用配體（例如抗體、胜肽和適體）的結合系統，用於主動靶向癌症特異性受體，例如 HER2、EGFR 和 CD44，從而實現個人化和精準的癌症治療策略。

新興技術如何擴展癌症藥物傳遞的能力？

技術融合正在迅速擴大NDDS在腫瘤學領域的應用範圍和有效性。能夠響應pH值、溫度、酵素和氧化還原梯度等刺激的智慧奈米顆粒，能夠根據腫瘤微環境客製化按需釋放藥物。例如，pH敏感的脂質體在血液循環中穩定，但在腫瘤的酸性環境中釋放其有效載荷。磁感應藥物載體和超音波觸發奈米氣泡也正在研究中，用於微創局部給藥。

另一個前沿領域是將影像功能與藥物傳遞結合，從而建構集診斷和治療於一體的診療平台。此類系統可即時監測藥物分佈和腫瘤反應，從而製定個人化治療方法。此外，基於幹細胞和樹突狀細胞的外泌體遞送平台因其固有的生物相容性和逃避免疫檢測的能力，正在被探索，有望提供一種類似隱形的藥物遞送方法。

生物分解性的水凝膠、可植入的儲存庫和可吸入的奈米顆粒正在拓展靜脈注射以外的給藥途徑。這些系統提高了患者的依從性，並能夠為膠質母細胞瘤、胰腺癌和大腸直腸癌等固體癌提供局部緩釋性。因新冠疫苗而普及的載mRNA脂質奈米顆粒，如今正被重新用於癌症免疫療法，以遞送腫瘤特異性抗原並刺激T細胞反應。

哪些癌症類型和治療方法促使人們採用 NDDS？

乳癌、肺癌、卵巢和胰腺癌等固體癌因其獨特的微環境和既定的分子標靶而處於 NDDS 整合的前沿。脂質體阿黴素（例如Doxil）和白蛋白結合Abraxane（ Abraxane ）是 NDDS 的商業性成功案例，與傳統化療相比，它們已證明具有安全性並可改善無惡化生存期。 HER2 標靶抗體藥物複合體(ADC)，例如 ado-trastuzumab emtansine（ Kadcyla ），透過受體結合和細胞內細胞毒性的雙重作用，正在徹底改變 HER2 陽性乳癌的治療。

白血病和淋巴瘤等骨髓惡性腫瘤也受益於奈米顆粒包裹的藥物和標靶蛋白質分解劑。 CAR-T細胞療法和免疫查核點抑制劑擴大得到奈米顆粒遞送系統的支持，用於調節腫瘤相關巨噬細胞或遞送siRNA來下調免疫抑制基因。轉移性和抗藥性癌症的研究尤其活躍，多藥奈米顆粒系統正被設計用於克服排放泵和腫瘤異質性。

從地區來看，美國在臨床試驗活動和商業化部署方面均處於領先地位，這得益於美國食品藥物管理局（FDA）的核准和美國國家癌症研究所的資助。歐洲緊隨其後，對精準醫療計畫提供了強力的監管支持。在亞太地區，中國、日本和韓國等國家正大力投資奈米醫學新興企業和製造基礎設施，加速區域創新並進入全球市場。

推動癌症治療領域 NDDS 全球市場成長的因素有哪些？

全球癌症治療新型藥物輸送系統市場的成長受到多種因素的推動，包括癌症發病率上升、抗癌藥物研發線不斷擴展以及支持標靶治療的臨床證據日益增多。對微創和個人化治療方案日益成長的需求，推動了對符合現代腫瘤學目標的先進輸送平台的投資。

製藥公司正在利用 NDDS 來改善藥物，延長專利期限，開拓新的適應症，並在競爭激烈的治療環境中實現產品線的差異化。生技新興企業、學術研究機構和大型製藥公司之間的策略聯盟正在加速從實驗室規模創新到臨床及商業部署的轉化進程。監管機構也展現出靈活性，根據突破性療法和加速核准途徑核准NDDS。

此外，付款人對基於結果的模型的興趣正在為高成本、高效的NDDS療法創造有利的報銷環境。隨著數據分析和數位生物標記物改善患者分層，這些系統將成為精準腫瘤學的基礎。在材料科學、生物工程和人工智慧驅動的藥物最佳化的推動下，癌症治療領域的NDDS市場預計將在多種腫瘤類型、治療環境和地理範圍內強勁擴張。

部分

產品類型（奈米顆粒、栓塞顆粒）

受訪公司範例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Co.
  • BioNTech SE
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Celsion Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • Ipsen
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

人工智慧整合

全球產業分析師正在利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP39108

Global Novel Drug Delivery Systems in Cancer Therapy Market to Reach US$64.5 Billion by 2030

The global market for Novel Drug Delivery Systems in Cancer Therapy estimated at US$21.3 Billion in the year 2024, is expected to reach US$64.5 Billion by 2030, growing at a CAGR of 20.3% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$35.8 Billion by the end of the analysis period. Growth in the Embolization Particles segment is estimated at 23.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 26.9% CAGR

The Novel Drug Delivery Systems in Cancer Therapy market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$15.0 Billion by the year 2030 trailing a CAGR of 26.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.9% CAGR.

Global Novel Drug Delivery Systems in Cancer Therapy - Key Trends & Drivers Summarized

Why Are Traditional Cancer Treatments Being Disrupted by Novel Drug Delivery Systems?

Conventional chemotherapy has long been plagued by systemic toxicity, poor bioavailability, and lack of tumor specificity-issues that compromise treatment efficacy and patient quality of life. Novel drug delivery systems (NDDS) are rapidly emerging as transformative technologies in oncology, offering targeted delivery of anticancer agents directly to tumor sites while minimizing damage to healthy tissues. By enhancing pharmacokinetics and overcoming drug resistance mechanisms, NDDS have redefined how clinicians approach complex and heterogeneous cancer types.

Among the most significant innovations are nanocarriers such as liposomes, dendrimers, micelles, and polymeric nanoparticles, which encapsulate cytotoxic agents and enable controlled release at the tumor microenvironment. These systems exploit the Enhanced Permeability and Retention (EPR) effect observed in solid tumors to achieve site-specific delivery. The result is a higher therapeutic index and reduced off-target toxicity. Additionally, conjugated systems using ligands such as antibodies, peptides, or aptamers are being developed to achieve active targeting of cancer-specific receptors like HER2, EGFR, and CD44, thereby enabling personalized and precision oncology strategies.

How Are Emerging Technologies Expanding Capabilities in Cancer Drug Delivery?

Technological convergence is rapidly enhancing the scope and efficacy of NDDS in oncology. Smart nanoparticles that respond to stimuli such as pH, temperature, enzymes, or redox gradients are enabling on-demand drug release, tailored to the tumor’s microenvironment. pH-sensitive liposomes, for instance, remain stable in circulation but release payloads in the acidic milieu of tumors. Magnetically guided drug carriers and ultrasound-triggered nanobubbles are also under investigation for localized delivery with minimal invasiveness.

Another frontier is the integration of imaging capabilities with drug delivery, leading to theranostic platforms that combine diagnosis and therapy in a single system. These systems allow for real-time monitoring of drug distribution and tumor response, enabling adaptive treatment regimens. Additionally, exosome-based delivery platforms derived from stem cells or dendritic cells are being explored for their innate biocompatibility and ability to bypass immune detection, providing a stealth-like approach to drug transport.

Biodegradable hydrogels, implantable reservoirs, and inhalable nanoparticles are extending delivery routes beyond intravenous administration. These systems improve patient compliance and enable localized, sustained-release formulations for solid tumors such as glioblastoma, pancreatic, and colorectal cancers. mRNA-loaded lipid nanoparticles, popularized by COVID-19 vaccines, are now being repurposed for cancer immunotherapy to deliver tumor-specific antigens and stimulate T-cell responses.

Which Cancer Types and Therapies Are Leading Adoption of NDDS?

Solid tumors such as breast, lung, ovarian, and pancreatic cancers are at the forefront of NDDS integration due to their well-defined microenvironments and established molecular targets. Liposomal doxorubicin (e.g., Doxil) and albumin-bound paclitaxel (Abraxane) are commercially successful examples of NDDS that have demonstrated improved safety and progression-free survival compared to traditional chemotherapies. HER2-targeted antibody-drug conjugates (ADCs), such as ado-trastuzumab emtansine (Kadcyla), are revolutionizing treatment for HER2-positive breast cancer, offering dual action through receptor binding and intracellular cytotoxicity.

Hematological malignancies like leukemia and lymphoma are also benefiting from nanoparticle-encapsulated drugs and targeted protein degraders. CAR-T cell therapy and immune checkpoint inhibitors are increasingly being supported by NDDS to modulate tumor-associated macrophages or deliver siRNA that downregulates immunosuppressive genes. Research is particularly intense in metastatic and drug-resistant cancers, where multi-drug nanoparticle systems are being engineered to overcome efflux pumps and tumor heterogeneity.

Regionally, the United States leads in both clinical trial activity and commercial deployment, supported by FDA approvals and National Cancer Institute funding. Europe follows with strong regulatory backing for precision medicine initiatives. In Asia-Pacific, countries like China, Japan, and South Korea are investing heavily in nanomedicine startups and manufacturing infrastructure to accelerate local innovation and global market participation.

What Is Fueling Growth in the Global Market for NDDS in Cancer Therapy?

The growth in the global novel drug delivery systems market for cancer therapy is driven by several factors, including escalating cancer prevalence, expanding oncology drug pipelines, and increasing clinical evidence supporting targeted therapies. Rising demand for minimally invasive, personalized treatment options has catalyzed investment in advanced delivery platforms that align with modern oncology goals.

Pharmaceutical companies are leveraging NDDS to extend patent life through drug reformulation, enter new indications, and differentiate their pipelines in a crowded therapeutic landscape. Strategic collaborations between biotech startups, academic labs, and pharmaceutical giants are accelerating the translational journey from lab-scale innovation to clinical and commercial deployment. Regulatory agencies are also demonstrating flexibility by approving NDDS under breakthrough therapy and accelerated approval pathways.

Moreover, payer interest in outcomes-based models is creating a favorable reimbursement climate for high-cost but high-efficacy NDDS therapies. As data analytics and digital biomarkers improve patient stratification, these systems will become cornerstones of precision oncology. With advances in materials science, bioengineering, and AI-driven drug optimization, the NDDS market in cancer therapy is poised for robust expansion across multiple tumor types, treatment settings, and geographies.

SCOPE OF STUDY:

The report analyzes the Novel Drug Delivery Systems in Cancer Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Nanoparticles, Embolization Particles)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Co.
  • BioNTech SE
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Celsion Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • Ipsen
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Novel Drug Delivery Systems in Cancer Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surging Oncology Pipeline Throws the Spotlight on Novel Drug Delivery Systems in Cancer Therapy
    • Limitations of Conventional Chemotherapy Propel Investment in Targeted Delivery Innovations
    • Advances in Nanotechnology and Lipid Nanoparticles Accelerate Growth in Next-Gen Platforms
    • Rising Adoption of Immuno-Oncology and mRNA-Based Therapies Drives Development of Specialized Carriers
    • Collaboration With Biopharma Innovators Strengthens Commercialization of Delivery Technologies
    • Regulatory Approvals for Injectable Depot Systems Expand Use in Long-Term Cancer Management
    • Surge in Precision Medicine Initiatives Spurs Use of Patient-Specific Drug Delivery Systems
    • Tumor Microenvironment Research Accelerates Innovation in Site-Specific Delivery Vectors
    • Integration of pH-Responsive and Thermosensitive Materials Enhances Delivery Accuracy
    • Biodegradable Polymers and Carrier Systems Gain Traction for Controlled Release Applications
    • Expansion of Companion Diagnostics Market Enables Alignment With Delivery-Optimized Formulations
    • Development of Smart Capsules and Microneedle Arrays Supports Non-Invasive Delivery Modes
    • Growth in Oncology Trials Utilizing Nano-Carriers Propels Technological Validation
    • Partnerships With CDMOs Fuel Scale-Up and GMP Manufacturing of Novel Delivery Modalities
    • Government Funding for Next-Generation Oncology Platforms Strengthens Industry R&D
    • Patient Demand for Reduced Side Effects and Enhanced QoL Drives Preference for Targeted Delivery
    • Focus on Drug-Device Combination Products Expands Integration Across Multiple Delivery Routes
    • Rise in Orphan Cancer Drug Development Spurs Innovation in Niche Delivery Systems
    • Market Differentiation Strategies Among Pharma Players Fuel Investment in Novel Carriers
    • Shift Toward Outpatient Oncology Treatment Models Propels Demand for Sustained Release Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Novel Drug Delivery Systems in Cancer Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Embolization Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • JAPAN
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • CHINA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • EUROPE
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • FRANCE
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • GERMANY
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • INDIA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • AFRICA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030

IV. COMPETITION